Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.58 |
| ▸ | RAF1 | P04049 | 9/20 | 0.58 |
| ▸ | SRC | P12931 | 5/20 | 0.53 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545829 | 0.95 | RAF1 (0.58) | BRAFRAF1SRCABL1CDK1 | |
| SCHEMBL10200174 | 0.94 | RAF1 (0.57) | BRAFRAF1SRCABL1CDK1 | |
| SCHEMBL14493297 | 0.91 | BRAF (0.64) | BRAFRAF1KDR | |
| SCHEMBL10200185 | 0.89 | BRAF (0.62) | BRAFRAF1KDR | |
| SCHEMBL546225 | 0.87 | BRAF (0.62) | BRAFRAF1SRCABL1CDK1 | |
| SCHEMBL545588 | 0.85 | BRAF (0.80) | BRAFRAF1SRCABL1CDK1 | |
| SCHEMBL545766 | 0.85 | BRAF (0.58) | BRAFRAF1KDR | |
| SCHEMBL545179 | 0.85 | BRAF (0.70) | BRAFRAF1KDR | |
| SCHEMBL547123 | 0.85 | BRAF (0.70) | BRAFRAF1KDR | |
| SCHEMBL545791 | 0.85 | BRAF (0.70) | BRAFRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885SRC 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.